Resmed Stock News

ResMed (RMD) delivered earnings and revenue surprises of 0% and 3.92%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

In a day of a widespread market selloff, ResMed <> is trading flat after Bank of America and JPMorgan upgraded the dual-listed medical device maker amid a product recall of a

The three major U.S. equities indexes closed lower again on Friday for the fourth day in a row.

ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ResMed <> was upgraded at Robert W. Baird to Outperform from Neutral with a price target of $300, up from $270.CLSA also upgraded the company to Buy.Baird analyst Mike Polark

The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2022 on Thursday,

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Investors are optimistic about ResMed's (RMD) strong sales in its mask product offering and growing uptake of its digital health solutions.

Respiratory Devices Market report includes major data, present request trends, terrain, technological invention, forthcoming technologies and the specialized progress in the affiliated assiduity. Respiratory Devices Market offers complete, complete report delivering request exploration data that''s applicable for new request entrants

Vontobel Holding Ltd. trimmed its holdings in ResMed Inc. (NYSE:RMD) by 26.3% in the third quarter, HoldingsChannel.com reports. The firm owned 6,247 shares of the medical equipment providers stock after selling 2,233 shares during the quarter. Vontobel Holding Ltd.s holdings in ResMed were worth $1,646,000 as of its most recent SEC filing. A number of []

Strs Ohio trimmed its position in ResMed Inc. (NYSE:RMD) by 10.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,582 shares of the medical equipment providers stock after selling 299 shares during the quarter. Strs Ohios holdings in ResMed were worth $680,000 as []

Profiles of major market players operating in the medical oxygen cylinder market, which include Drive DeVilbiss Healthcare, Inc., Philips Healthcare, Invacare Corporation, Nidek Medical, Inogen, Inc., AirSep Corporation, ResMed, Medical Depot, Inc., CAIRE Inc., O2 CONCEPTS, OxyGo, LLC, Precision Medical, Inc., Linde plc, CDMI Profiles of major market players operating in the medical oxygen cylinder market, which include Drive DeVilbiss Healthcare, Inc., Philips Healthcare, Invacare Corporation, Nidek Medical, Inogen, Inc., AirSep Corporation, ResMed, Medical Depot, Inc., CAIRE Inc., O2 CONCEPTS, OxyGo, LLC, Precision Medical, Inc., Linde plc, CDMI